Dualitas: Advancing immune modulation by inducing proximity of two cell surface targets

Dualitas, a South San Francisco biotech launched Tuesday with $65 million in series A financing, is screening for new combinations of cell surface targets for bispecific antibodies that leverage proximity biology mechanisms to achieve durable effects in inflammation and immunology indications.

Versant Ventures and Qiming Venture Partners USA co-led the financing, which the company will use to advance its lead candidates in autoimmune and allergic disease into the clinic...